The Claim
In obese Chinese adults, 12 weeks of liraglutide monotherapy at 1.8 mg/day is associated with significant reductions in fasting blood glucose by 0.62 mmol/L, 2-hour post-load glucose by 2.95 mmol/L, and HbA1c by 0.59%, indicating a clinically relevant improvement in glucose metabolism.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In obese Chinese adults, taking liraglutide at 1.8 mg daily for 12 weeks lowers fasting blood glucose by 0.62 mmol/L, reduces 2-hour post-meal glucose by 2.95 mmol/L, and decreases HbA1c by 0.59%, which represents a measurable improvement in glucose metabolism.
See the scientific wording
In obese Chinese adults, 12 weeks of liraglutide monotherapy at 1.8 mg/day is associated with significant improvements in fasting blood glucose, 2-hour post-load glucose, and HbA1c, with mean reductions of 0.62 mmol/L, 2.95 mmol/L, and 0.59%, respectively, indicating a clinically relevant improvement in glucose metabolism.
Liraglutide lowers fat buildup in the liver, which removes a block that prevents insulin from working properly. Once insulin can signal correctly, the liver stops making too much glucose, causing blood sugar levels to drop.
What the research says
1 studyThis study found that obese Chinese adults who took liraglutide for 12 weeks had better blood sugar levels, just like the claim says. Even though it doesn’t give the exact numbers, it clearly shows blood sugar improved a lot.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.